Assessing non-cancer-related health status of US cancer patients: Other-cause survival and comorbidity prevalence

American Journal of Epidemiology

Volumn 178, Issue 3, 2013, Pages 339-349

  Cho, Hyunsoon ^a   Mariotto, Angela B ^a   Mann, Bhupinder S ^a   Klabunde, Carrie N ^a   Feuer, Eric J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer survival; cancer survivorship; comorbidity; health status; left truncated survival; non cancer related survival; other cause mortality; SEER

Indexed keywords

ASSESSMENT METHOD; CANCER; DATA SET; DISEASE PREVALENCE; EPIDEMIOLOGY; HEALTH STATUS; SURVIVAL;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; COLORECTAL CANCER; COMORBIDITY; DISEASE SEVERITY; FEMALE; HAZARD ASSESSMENT; HEALTH STATUS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICARE; PREVALENCE; PROSTATE CANCER; SURVIVAL RATE; UNITED STATES;

CANCER SURVIVAL; CANCER SURVIVORSHIP; COMORBIDITY; HEALTH STATUS; LEFT-TRUNCATED SURVIVAL; NON-CANCER-RELATED SURVIVAL; OTHER-CAUSE MORTALITY; SEER;

AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CAUSE OF DEATH; COLORECTAL NEOPLASMS; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; LIFE TABLES; LUNG NEOPLASMS; MALE; MEDICARE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; NEOPLASM STAGING; PARALYSIS; PREVALENCE; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES; VASCULAR DISEASES;

UNITED STATES;

EID: 84881156931     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws580     Document Type: Article

References (41)

1. Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730-756.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011. (http://seer.cancer. gov/csr/1975-2008/). (Accessed February 1, 2012).
3. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-128.
4. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-241.
5. Marubini E, Valsecchi MG. Analyzing Survival Data from Clinical Trials and Observational Studies. New York; Chichester: JohnWiley & Sons; 1995.
6. Begg CB, Schrag D. Attribution of deaths following cancer treatment. J Natl Cancer Inst. 2002;94(14):1044-1045.
7. Percy C, Stanek E, Gloeckler L. Accuracy of cancer death certificates and its effect on cancer mortality statistics. Am J Public Health. 1981;71(3):242-250.
8. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101-121.
9. Dignam JJ, Huang L, Ries L, et al. Estimating breast cancerspecific and other-cause mortality in clinical trial and population-based cancer registry cohorts. Cancer. 2009; 115(22):5272-5283.
10. Howlader N, Ries LAG, Mariotto AB, et al. Improved estimates of cancer-specific survival rates from populationbased data. J Natl Cancer Inst. 2010;102(20):1584-1598.
11. Argiris A, Brockstein BE, Haraf DJ, et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin Cancer Res. 2004;10(6):1956-1962.
12. Du XL, Fox EE, Lai DJ. Competing causes of death for women with breast cancer and change over time from 1975 to 2003. Am J Clin Oncol. 2008;31(2):105-116.
13. Hollingsworth JM, Miller DC, Daignault S, et al. Five-year survival after surgical treatment for kidney cancer-a population-based competing risk analysis. Cancer. 2007; 109(9):1763-1768.
14. Mell LK, Dignam JJ, Salama JK, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010;28(1):15-20.
15. Ng AK, Bernardo MP,Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108.
16. National Cancer Institute. SEER Registry Groupings for Analyses. Bethesda, MD: National Cancer Institute. (http://seer. cancer.gov/registries/ terms.html). (Accessed June 4, 2013).
17. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145(1):72-80.
18. Lamarca R, Alonso J, Gomez G, et al. Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population. J Gerontol A Biol Sci Med Sci. 1998;53(5): M337-M343.
19. SAS Institute, Inc. SAS/STAT 9.2 User's Guide. Cary, NC: SAS Institute, Inc.; 2008.
20. Arias E, Curtin LR,Wei R, et al. U.S. decennial life tables for 1999-2001, United States life tables. Natl Vital Stat Rep. 2008;57(1):1-36.
21. Elandt-Johnson RC, Johnson NL. Survival Models and Data Analysis. New York, NY: JohnWiley & Sons; 1999.
22. National Cancer Institute. SEER-Medicare Linked Database. Bethesda, MD: National Cancer Institute; 2011. (http://healthservices.cancer.gov/seermedicare/ ). (Accessed June 2010).
23. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5): 373-383.
24. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267.
25. Klabunde CN, Legler JM,Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584-590.
26. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV-3-IV-8.
27. Mariotto AB,Wang Z, Klabunde CN, et al. Health-adjusted age: a tool for assessing non-cancer survival of recently diagnosed cancer patients. J Clin Epidemiol. In press.
28. Cronin KA, Feuer EJ. Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000;19(13): 1729-1740.
29. Chen AY, Schrag NM, Halpern MT, et al. The impact of health insurance status on stage at diagnosis of oropharyngeal cancer. Cancer. 2007;110(2):395-402.
30. Halpern MT,Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9(3):222-231.
31. Cronin KA, Krebs-Smith SM, Feuer EJ, et al. Evaluating the impact of population changes in diet, physical activity, and weight status on population risk for colon cancer (United States). Cancer Causes Control. 2001;12(4): 305-316.
32. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am. 2002;31(4):925-943.
33. Giovannucci E, Ascherio A, Rimm EB, et al. Physical-activity, obesity, and risk for colon-cancer and adenoma in men. Ann Intern Med. 1995;122(5):327-334.
34. Giovannucci E, Colditz GA, Stampfer MJ, et al. Physical activity obesity and risk of colorectal adenoma in women (United States). Cancer Causes Control. 1996;7(2): 253-263.
35. Giovannucci E,Willett WC, Stubbs A. Dietary factors and risk of colon-cancer. Ann Med. 1994;26(6):443-452.
36. Breen N,Wagener DK, Brown ML, et al. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst. 2001;93(22): 1704-1713.
37. Swan J, Breen N, Graubard BI, et al. Data and trends in cancer screening in the United States. Cancer. 2010;116(20): 4872-4881.
38. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570-1595.
39. Iribarren C, Tekawa IS, Sidney S, et al. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med. 1999;340(23):1773-1780.
40. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Public Health Service Publication No. 1103.Washington, DC: United States Department of Health, Education, andWelfare, Public Health Service; 1964.
41. National Cancer Institute. Site Recode ICD-O-3 (1/27/2003) Definition. Bethesda, MD: National Cancer Institute; 203. ((http://seer.cancer.gov/ siterecode/icdo3-d01272003/). (Accessed June 4, 2013).